复方环磷酰胺片+醋酸泼尼松片联合白芍总苷胶囊治疗系统性红斑狼疮对患者外周血CD3^(-)CD16^(+)CD56^(+)NK细胞水平的影响  

Effect of Compound Cyclophosphamide Tablets+Prednisone Acetate Tablets combined with Total Glucosides of Paeony Capsules on CD3^(-)CD16^(+)CD56^(+)NK cell in peripheral blood of patients with systemic lupus erythematosus

作　　者：徐焱 陈福英 万峻宏 XU Yan;CHEN Fuying;WAN Junhong(Teaching and Research Office of Internal Medicine,Jiangxi Medical College,Jiangxi Province,Shangrao334000,China)

机构地区：[1]江西医学高等专科学校内科教研室,江西上饶334000

出　　处：《中国当代医药》2023年第32期52-55,60,共5页China Modern Medicine

基　　金：江西省卫生健康委科技计划项目(202141026)。

摘　　要：目的探究复方环磷酰胺片+醋酸泼尼松片联合白芍总苷胶囊治疗系统性红斑狼疮的疗效及对患者外周血CD3-CD16^(+)CD56^(+)NK细胞水平的影响。方法选取2021年3月至2022年6月上饶市人民医院收治的60例系统性红斑狼疮患者作为研究对象,采用单双号法均分为对照组(30例)及联合组(30例)。对照组患者应用复方环磷酰胺片+醋酸泼尼松片的治疗方案,联合组患者在对照组的基础上联用白芍总苷胶囊进行治疗。比较两组患者治疗前后的系统性红斑狼疮病情活动程度(SLEDAI)评分、外周血CD3^(-)CD16^(+)CD56^(+)NK细胞水平及其百分比、炎症因子[白细胞介素-4(IL-4)、白细胞介素-10(IL-10)、肿瘤坏死因子-α(TNF-α)、γ干扰素(INF-γ)]水平及治疗期间不良反应发生情况。结果两组患者治疗6个月后的SLEDAI评分、IL-4、IL-10、TNF-α、INF-γ水平低于本组治疗前,差异有统计学意义(P<0.05),且联合组治疗后的SLEDAI评分、IL-4、IL-10、TNF-α、INF-γ水平低于对照组,差异有统计学意义(P<0.05)。两组患者治疗6个月后的外周血CD3-CD16^(+)CD56^(+)NK细胞数量及其百分比高于本组治疗前,差异有统计学意义(P<0.05),且联合组治疗后的外周血CD3-CD16^(+)CD56^(+)NK细胞数量及百分比高于对照组,差异有统计学意义(P<0.05)。两组患者治疗期间不良反应总发生率比较,差异无统计学意义(P>0.05)。结论复方环磷酰胺片+醋酸泼尼松片联合白芍总苷胶囊治疗系统性红斑狼疮可有效减轻患者病情严重程度,改善自身免疫功能并减少炎症反应,该方案安全有效,建议临床推广应用。Objective To explore the efficacy of Compound Cyclophosphamide Tablets+Prednisone Acetate Tablets combined with Total Glucosides of Paeony Capsules in the treatment of systemic lupus erythematosus and the effects on peripheral blood CD3-CD16^(+)CD56^(+)NK cell.Methods Sixty patients with systemic lupus erythematosus admitted to Shangrao People's Hospital from March 2021 to June 2022 were selected as the study objects,and they were divided into control group(30 cases)and combination group(30 cases)by odd-even method.The control group was treated with Compound Cyclophosphamide Tablets+Prednisone Acetate Tablets,and the combined group was treated with Total Glucosides of Paeony Capsules on the basis of the control group.Degree of systemic lupus erythematosus disease activity(SLEDAI)score,peripheral blood CD3^(-)CD16^(+)CD56^(+)NK cell level and percentage,inflammatory factors(interleukin-4[IL-4],interleukin-10[IL-10],tumor necrosis factor-α[TNF-α],interferon-γ[INF-γ])levels and occurrence of adverse reactions during treatment were compared between the two groups before and after treatment.Results After 6 months of treatment,the SLEDAI score,IL-4,IL-10,TNF-αand INF-γlevels of the two groups were lower than those before treatment,the differences were statistically significant(P<0.05),and the SLEDAI score,IL-4,IL-10,TNF-αand INF-γlevels of the combined group were lower than those of the control group,the differences were statistically significant(P<0.05).After 6 months of treatment,the number and percentage of peripheral blood CD3-CD16^(+)CD56^(+)NK cells in the two groups were higher than those before treatment,the differences were statistically significant(P<0.05),and the number and percentage of peripheral blood CD3-CD16^(+)CD56^(+)NK cells in the combined group were higher than those in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Compound Cyclophosphamide Tab

关 键 词：环磷酰胺 糖皮质激素 白芍总苷胶囊 系统性红斑狼疮 淋巴细胞亚群 

分 类 号：R593.24[医药卫生—内科学]